Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The C the Signs platform has demonstrated high sensitivity in early detection of several cancers. For example, it identified up to 20.7% of breast cancers five years earlier than standard pathways and improved early-stage ovarian cancer diagnosis by over 53%. In a study with nearly 900,000 patients’ records from Mayo Data Platform, its colorectal model achieved a sensitivity of 93.8%, comparable to colonoscopy. The system has been used for over 100,000 patient risk assessments annually and detected thousands of cases within NHS primary care settings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on C the Signs.